Bruce Gellin, M.D., M.P.H., president of Global Immunization at the Sabin Vaccine Institute (Sabin) and former Deputy Assistant Secretary for Health and Director of the National Vaccine Program Office at the U.S. Department of Health and Human Services (HHS), testified on July, 14, 2020, at the House Subcommittee on Economic and Consumer Policy’s briefing entitled “Guardrails to Ensure a Safe and Effective COVID-19 Vaccine.”

WASHINGTON, D.C. — In response to the harmful and impulsive decision to withdraw funds from the World Health Organization (WHO), the Sabin Vaccine Institute (Sabin) joins the Center for Health and Gender Equity (CHANGE) and more than 65 other non-governmental organizations and global health institutions in an official letter of solidarity to WHO Director-General Dr. Tedros Adhanom Ghebreyesus and WHO staff worldwide.

In our strongest and most unified voice, the Sabin Vaccine Institute condemns racism. Dr. Albert Sabin was a great scientist, and importantly his work led him to fight for equality so that all children everywhere – regardless of race, religion, nationality, gender or socioeconomic status – received his lifesaving polio vaccine.

WASHINGTON, D.C. and ROME, Italy, May 13, 2020 – The Sabin Vaccine Institute (Sabin) and its partner ReiThera Srl today announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, has exercised the first two options, valued at $20 million, under the 2019 contract to advance the development of vaccines against Ebola Sudan and Marburg viruses through Phase 2 clinical trials.